BIO-UV Group (ALTUV) H1 2025 earnings summary

Executive summary

• EBITDA margin improved to 17.3% in H1 2025, up from 17.1% in H1 2024, reflecting operational efficiency and cost control.

• Net income surged by 258% year-over-year to €1.3M, with net margin rising to 6.6%.

• Revenue declined 8% year-over-year to €20.4M, impacted by a weak pool market and end of maritime retrofit projects.

Financial highlights

• EBITDA reached €3.5M in H1 2025, down 8% year-over-year, but margin improved.

• Operating income increased 6% to €2.0M, with operating margin at 9.9%.

• Free cash flow for H1 2025 was €1.0M; net cash position improved by €5.5M.

• Net financial debt reduced to €9.1M, with gearing ratio down to 22% from 53% at end-2024.

Outlook and guidance

• Targeting slight organic revenue growth for full-year 2025, driven by Solutions and Services divisions.

• Expects improved profitability and continued deleveraging, with focus on working capital optimization.

• Plans to resume external growth initiatives, especially in North America, leveraging recent capital raise.